TOMAS BERL, M. D.; ARNOLD S. BERNS, M.D.; WILLIAM E. HUFFER, M.D.; KAREN HAMMILL, R.N.; ALLEN C. ALFREY, M.D., F.A.C.P.; CLAUDE D. ARNAUD, M.D., F.A.C.P.; ROBERT W. SCHRIER, M.D., F.A.C.P.
BERL T, BERNS AS, HUFFER WE, HAMMILL K, ALFREY AC, ARNAUD CD, et al. 1,25 Dihydroxycholecalciferol Effects in Chronic Dialysis: A Double-Blind Controlled Study. Ann Intern Med. 1978;88:774-780. doi: 10.7326/0003-4819-88-6-774
Download citation file:
Published: Ann Intern Med. 1978;88(6):774-780.
1,25 dihydroxycholecalciferol [1,25(OH)2D3] was studied in a double-blind controlled fashion in patients on chronic dialysis. Serum calcium was unchanged in 16 patients on vitamin D3(D3) (400 to 1200 IU/day). In 15 patients on 1,25(OH)2D3 (0.5 to 1.5 µg/day), serum calcium increased from 9.05 ± .15 to 10.25 ± .20 mg/dl (p < 0.001), returning to 9.37 ± .16 mg/dl (p < 0.001) in the post control period. Patients on D3 showed no reversible decrease in immunoreactive parathyroid hormone levels, but patients on 1,25(OH)2D3 did, from a control of 1077 ± 258 to 595 ± 213 µl equivalents/ml (p < 0.01), and returned to 1165 ± 271 µl equivalents/ml (p < 0.005). Nine of 12 patients on D3 who underwent serial iliac-crest biopsies showed histologic deterioration, and six of seven who received 1,25(OH)2D3 were improved or unchanged (p < 0.025). Bone mineral and calcium decreased in patients on D3 (p < 0.05) but not in those on 1,25(OH)2D3. Hypercalcemia occurred in five of 15 patients. We conclude that 1,25(OH)2D3 has a calcemic effect in chronic dialysis patients, decreases levels of immunoreactive parathyroid hormone, and is associated with histologic improvement in bone disease. Thus, 1,25(OH)2D3 is a valuable adjunct to the management of renal osteodystrophy but requires monitoring of serum calcium to avoid hypercalcemia.
Learn more about subscription options.
Register Now for a free account.
Nephrology, Renal Replacement Therapy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only